Synpromics Chardan Leadership Call No Images? Click here The future of gene therapy is synthetic promoters (and Synpromics)David Venables and Michael Roberts joined Chardan’s Gbola Amusa, MD, CFA for a Leadership Call to discuss synthetic promoters and their importance in gene therapy. Below is a preview of Chardan’s industry note on Synpromics and the future of gene therapy being synthetic promoters (and Synpromics). Key PointsOn 25 February 2019, Chardan hosted a Leadership Call with David Venables, PhD (CEO), and Michael Roberts, PhD (Founder & CSO) of Synpromics (private). Synpromics has established itself as the leader in the design and development of synthetic promoters, which enable unprecedented control of gene expression, for example in gene therapy (GT) applications. The company has developed PromPT, a platform that leverages the power of big data, bioinformatics, and machine learning to design and construct next-generation synthetic promoters. Synpromics has partnerships with >10 leading gene therapy companies, including uniQure (Buy, a Chardan Top Pick for 2019), which is utilizing a synthetic promoter developed by Synpromics in its gene therapy candidate for hemophilia A. We find Synpromics to be one of the most important companies for investors to know and understand, given our view of "an expansion in the importance of synthetic biology (promoters, transgenes, switches) and artificial intelligence (AI) [in genetic medicines]". A replay of the Leadership Call can be accessed here. If you’d like to find out more about our technology and recent developments, David Venables will be presenting at ARM’s Cell & Gene Therapy Investor Day in New York this Thursday. Get in touch to arrange a meeting while he’s there. |